Lymphoma

Patients undergoing bone marrow biopsy would respond favorably to interventions intended to improve their experience, according to study results presented at TCT Meetings Digital Experience.

The uptake of chimeric antigen receptor T-cell therapy has been sluggish despite its tantalizing promise to provide a cure for a large proportion of patients with advanced large B-cell lymphoma.

Patients who developed AKI during hospitalization with hematologic malignancy experienced a significantly increased risk for kidney function decline and chronic kidney disease in the following year.

The FDA granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory large B-cell lymphoma who received at least two prior therapies.

The FDA granted accelerated approval to umbralisib for two types of relapsed or refractory lymphoma.

Challenges presented by the COVID-19 pandemic did not stop progress in research or clinical development of gene and cell therapies, according to a state-of-the-industry briefing by Alliance of Regenerative Medicine.

The FDA cleared an investigational new drug application for PBCAR19B, a chimeric antigen receptor T-cell therapy for patients with relapsed or refractory non-Hodgkin lymphoma, according to the agent’s manufacturer.

The FDA approved crizotinib for treatment of certain patients with systemic anaplastic large cell lymphoma.

Roswell Park Comprehensive Cancer Center announced the hiring or promotion of several people across clinical, administrative and research departments.

The Leukemia & Lymphoma has collaborated with cancer institutions, foundations and philanthropic individuals to fund several cancer research projects.